Notably, PPARα-based therapies such as clofibrate and fenofibrate have already been investigated for their anti-cancer effects in pancreatic cancer, with promising pre-clinical evidence in both cell lines and animal models [39]. This evidence concerns the gene PPARA and familial pancreatic carcinoma.